

TrialNet UK Participant Newsletter

You, or a member of your family, have taken part in the TrialNet Pathway to Prevention study, so we wanted to take this opportunity to update you on how the study is going in the UK and tell you about other recent TrialNet news.

TrialNet News

Since our last newsletter, we have welcomed Dr. Yuk-Fun Liu (below, left).

Dr. Liu is an honorary consultant and clinical lecturer in Diabetes and Endocrinology at Guy's Hospital, London and has joined the TrialNet team as a Co-Principal Investigator at the Clinical Centre in Bristol. Dr. Liu will work alongside Prof. Polly Bingley (below, right), the UK Chief Investigator for TrialNet.



Our UK Network is expanding!

We opened several new study sites across the UK in 2018, including 3 new main trial sites; St. George's London, Cardiff and Glasgow. Plus, we have 4 more sites aiming to open in early 2019!

Map (right) shows 62 TrialNet sites across the UK.


Blue & Green are Pathway to Prevention screening sites. Red is the Clinical Centre in Bristol.

TrialNet UK recruits their 10,000th participant!

In June 2018 we celebrated recruiting our 10,000th participant to the Pathway to Prevention Study in the UK. The UK remain the biggest recruiter to the study outside of the US. We would like to say a big thank you for your participation in the study.



William (left) and his twin brother Matthew were both screened at our Exeter site in April. William was our 10,000th UK participant - thank you both for participating in the Pathway to Prevention Study!



TrialNet at Diabetes UK

In March we presented at the Diabetes UK professional conference in Liverpool.

Chloe Gillum talked about how monitoring high-risk relatives in the Pathway to Prevention study is associated with less severe symptoms of type 1 diabetes at diagnosis. Our UK data shows that fewer than 2% of participants who develop T1D whilst being monitored present with diabetic ketoacidosis (DKA) compared to the previously reported UK figure of 25%.

You can view our full poster at:
www.bristol.ac.uk/translational-health-sciences/research/diabetes/research/trialnet/.

Hydroxychloroquine Prevention Study - opening in the UK in 2019


TrialNet are testing a drug called hydroxychloroquine (HCQ) to see if it can delay or prevent progression from stage 1 to stage 2, and ultimately prevent clinical diagnosis (stage 3) of diabetes. HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay type 1 diabetes.

Who can participate?

- 3 years of age or above
- Has 2 or more diabetes autoantibodies
- Has normal results on an Oral Glucose Tolerance Test
- Be able to swallow the drug capsule whole

For more information please visit

www.trialnet.org/our-research/prevention-studies/hydroxychloroquine-hcq.



ATG-GCSF New Onset Study - results

Although this TrialNet study was not open in the UK we wanted to share the 1-year study results with you. TrialNet researchers wanted to know if anti-thymocyte globulin (ATG, a drug used to prevent organ transplant rejection) given alone or in combination with granulocyte-colony stimulating factor (G-CSF, a drug used in patients receiving cancer therapy) could slow insulin loss in people diagnosed with type 1 diabetes within the past 100 days. 89 people, aged 12-45 years were enrolled.

Key findings at 1 year:

- Low-dose ATG alone preserved beta cell function and improved insulin production
- Low-dose ATG given with GCSF did not enhance beta cell preservation
- Low-dose ATG alone and ATG given with GCSF significantly reduced HbA1c levels compared to placebo

Next Steps:

- All participants have now completed their 2-year study visits (August 2018)
- Final results will be reported later this year

TrialNet is considering future studies to learn whether ATG given alone, or in combination with other drugs, will prevent or delay disease onset. To read the full published article reporting the 1-year results please visit <http://care.diabetesjournals.org/content/early/2018/07/13/dc18-0494.long>

TrialNet go GREEN in 2019!

We will be sending all future newsletters electronically, therefore if you received this newsletter by post please let us know your email address. We will only use your email address for study communications and will not share it with anyone else. You will also be able to read future newsletters via our University of Bristol web page at: www.bristol.ac.uk/translational-health-sciences/research/diabetes/research/trialnet/.



Contact us

TrialNet UK Clinical Centre, Diabetes and Metabolism, University of Bristol, Level 2, Learning and Research, Southmead Hospital, Bristol, BS10 5NB. Tel:0117 4147920, email: Trialnet-uk@bristol.ac.uk.

Find, like, share and tweet us!



www.trialnet.org



@T1D_TrialNet



YouTube DiabetesTrialNet